Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: A randomized placebo-controlled study

Atherosclerosis

Volumn 210, Issue 1, 2010, Pages 194-198

  Andreou, Ioannis ^a   Tousoulis, Dimitris ^a   Miliou, Antigoni ^a   Tentolouris, Costas ^a   Zisimos, Kostas ^a   Gounari, Panagiota ^a   Siasos, Gerasimos ^a   Papageorgiou, Nikos ^a   Papadimitriou, Christos A ^a   Dimopoulos, Meletios Athanasios ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Heart failure; Inflammation; Myeloperoxidase; Statins; Xanthine oxidase inhibitors

Indexed keywords

ALLOPURINOL; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CD40 LIGAND; INTERLEUKIN 6; MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; ROSUVASTATIN;

AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SYSTOLIC HEART FAILURE;

AGED; ALLOPURINOL; BIOLOGICAL MARKERS; CHOLESTEROL; CHOLESTEROL, LDL; CHRONIC DISEASE; FEMALE; FLUOROBENZENES; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MALE; PEROXIDASE; PYRIMIDINES; SULFONAMIDES; TRIGLYCERIDES;

EID: 77952430959     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.10.046     Document Type: Article

References (28)

1. Tousoulis D., Charakida M., Stefanadis C. Inflammation and endothelial dysfunction as therapeutic targets in patients with heart failure. Int J Cardiol 2005, 100:347-353.
2. Nicholls S.J., Hazen S.L. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005, 25:1102-1111.
3. Askari A.T., Brennan M.L., Zhou X., et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med 2003, 197:615-624.
4. Vasilyev N., Williams T., Brennan M.L., et al. Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation 2005, 112:2812-2820.
5. Tang W.H., Brennan M.L., Philip K., et al. Plasma myeloperoxidase levels in patients with chronic heart failure. Am J Cardiol 2006, 98:796-799.
6. Eleuteri E., Di Stefano A., Ricciardolo F.L., et al. Increased nitrotyrosine plasma levels in relation to systemic markers of inflammation and myeloperoxidase in chronic heart failure. Int J Cardiol 2009, 135:386-390.
7. Tang W.H., Tong W., Troughton R.W., et al. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol 2007, 49:2364-2370.
8. Zhang R., Brennan M.L., Fu X., et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001, 286:2136-2142.
9. Brennan M.L., Penn M.S., Van Lente F., et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003, 349:1595-1604.
10. Baldus S., Heeschen C., Meinertz T., et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003, 108:1440-1445.
11. Morrow D.A., Sabatine M.S., Brennan M.L., et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 2008, 29:1096-1102.
12. Node K., Fujita M., Kitakaze M., Hori M., Liao J.K. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003, 108:839-843.
13. Engberding N., Spiekermann S., Schaefer A., et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug?. Circulation 2004, 110:2175-2179.
14. Shishehbor M.H., Brennan M.L., Aviles R.J., et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003, 108:426-431.
15. Kutter D., Devaquet P., Vanderstocken G., et al. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit?. Acta Haematol 2000, 104:10-15.
16. Nikpoor B., Turecki G., Fournier C., Theroux P., Rouleau G.A. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 2001, 142:336-339.
17. Kumar A.P., Reynolds W.F. Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun 2005, 331:442-451.
18. Nahrendorf M., Sosnovik D., Chen J.W., et al. Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation 2008, 117:1153-1160.
19. Jung K.H., Chu K., Jeong S.W., et al. HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage. Stroke 2004, 35:1744-1749.
20. Zhou T., Zhou S.H., Qi S.S., et al. The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome. Clin Chim Acta 2006, 368:168-172.
21. Stenvinkel P., Rodriguez-Ayala E., Massy Z.A., et al. Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2006, 1:281-287.
22. Tousoulis D., Antoniades C., Bosinakou E., et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 2005, 178:359-363.
23. Tousoulis D., Charakida M., Stefanadi E., et al. Statins in heart failure. Beyond the lipid lowering effect. Int J Cardiol 2007, 115:144-150.
24. Olsson A.G. Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin Rosuvastatin. Am J Cardiol 2001, 87:33B-36B.
25. Harrison J.E., Schultz J. Studies on the chlorinating activity of myeloperoxidase. J Biol Chem 1976, 251:1371-1374.
26. Yiginer O., Ozcelik F., Inanc T., et al. Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clin Res Cardiol 2008, 97:334-340.
27. Meuwese M.C., Stroes E.S., Hazen S.L., et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007, 50:159-165.
28. Singh U., Devaraj S., Jialal I. C-reactive protein stimulates myeloperoxidase release from polymorphonuclear cells and monocytes: implications for acute coronary syndromes. Clin Chem 2009, 55:361-364.